Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1186 to 1200 of 1300 results for heart OR cardi* OR arrythmia

  1. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  2. What is the clinical and cost effectiveness of intermittent auscultation compared with continuous cardiotocography for women in labour who have had a previous caesarean section?

    effectiveness of intermittent auscultation compared with continuous cardiotocography for women in labour who have had a previous...

    Research recommendation
    Published
    16 August 2019

  3. What is the most effective dosage at which oxytocin should be recommenced once stopped in labour because of an abnormal cardiotocography?

    should be recommenced once stopped in labour because of an abnormal cardiotocography? Any explanatory notes(if applicable) For a short...

    Research recommendation
    Published
    11 January 2024

  4. Relaxation therapies: What is the clinical and cost effectiveness of relaxation therapies for managing primary hypertension in adults in terms of reducing cardiovascular events and improving quality of life?

    therapies for managing primary hypertension in adults in terms of reducing cardiovascular events and improving quality of life? Any...

    Research recommendation
    Published
    11 April 2022

  5. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

    Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    2 July 2025
    View recommendations

    Sections for TA1077

  6. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

    Technology appraisal guidance
    Discontinued

  7. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  8. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued

  9. Thrombophilia [ID393]

    Discontinued Reference number: GID-TAG374

    Technology appraisal guidance
    Discontinued

  10. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  11. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  12. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  13. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  14. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  15. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued